Table 2.
High performance liquid chromatography (HPLC) technique coupled with hollow fiber based extraction techniques for pharmaceutical drugs.
| Analyte | Preconcentration/Separation method | Membrane / SLM composition | Real applications | LODa | EF/PFb | LRc | Instrumental tec. | Ref. |
|---|---|---|---|---|---|---|---|---|
| Atenolol, betaxolol, propranolol | Microfluidic EME | NPOE + DEHP + TEHP | Urine, plasma | 4–10 μg/L | — | 10–850 μg/L | HPLC-UV | [66] |
| Amoxicillin, nicotinic acid, hippuric acid, salicylic acid, anthranilic acid, ketoprofen, naproxen, ibuprofen | EME | Chitosan membrane = 60% chitosan + 40% Aliquat®336 / 1-octanol | Urine | — | — | — | HPLC-DAD | [67] |
| Epinephrine, norepinephrine dopamine | Complexation mediate-EME, EME | TFPBA + DEHPi | Urine | 1.8–5 μg/L | 2.2–6 | — | HPLC-UV-MS | [68] |
| Tetracycline, chlortetracycline, doxycycline, oxytetracycline | HF-DLLME | Aliquat-336 + 1-octanol | Milk | 0.95–3.6 μg/L | — | — | HPLC-UV | [69] |
| 2-methyl hippuric acid, 3- methyl hippuric acid, 4- methyl hippuric acid | HFLPME | 1-octanol | Urine | 2–3 μg/L | 210–312 | 10–50,000 μg/L | HPLC-UV | [70] |
| Hippuric acid, mandelic acid | HF-LPME | 1-octanol + TBP | Urine | 0.007–0.009 μg/mL | 172–195 | 0.02–20 mg/L | HPLC-UV | [71] |
| 54 care products + pharmaceutical drugs | HFLSPME | 1-octanol + toluene | Fish, water | 0.31–1.61 μg/kg | 0.11–12.83 | — | HPLC-MS | [72] |
| Pramipexole | EME | RGO + NPOE | Water and urine samples | 0.04 and 0.14 ng/mL | 301 and 265 | 0.13–1000 ng/mL | HPLC-UV | [73] |
| Haloperidol, loperamide, methadone, nortriptyline, pethidine | EME | NPOE, TBP | — | — | — | — | HPLC-UV | [74] |
| Codeine, naloxone, naltrexone | PEME | DEHP + NPOE | Plasma, urine | 2–10 μg/L | — | 10.–500 μg/L | HPLC-UV | [75] |
| Rivastigmine, verapamil, amlodipine, morphine | EME | Agarose gel as SLM | Wastewater | 1.5–1.8 ng/mL | — | 5–1000 ng/mL | HPLC-UV | [76] |
| Nicotinic acid, amoxicillin, hippuric acid, salicylic acid | EME | Acrylic nanofibers membrane /Aliquat®336 + 1-octanol | Urine samples | 112–402.3 μg/L | — | 173.3–4000 μg/L | HPLC-DAD | [77] |
| Ephedrine, clonidine | On chip-EME | DEHP + NPOE | Urine, plasma | <11 μg/L | 12–19 | 10–500 μg/L | HPLC-UV | [78] |
| Imipramine, amitriptyline, chlorpromazine | μEME | Agarose film as membrane / 1-hexyl-3-methylimidazolium hexafluorophosphate | River and tap water | 0.1–0.4 μg/L | 110–150 | 1.0–1000 μg/L | HPLC-UV | [79] |
| Ibuprofen, sodium diclofenac | EME | C60 fullerene + 1-octanol | Urine | 9–10 ng/mL | 166–188 | 15–500 ng/mL | HPLC-UV | [80] |
| Ketoprofen, diclofenac, ibuprofen, mefenamic acid | EME | Agarose film / 1-octanol | River and tap water | 0.14–0.42 | 62–86 | 0.5–500 | HPLC-UV | [81] |
| Verapamil, Haloperidol, rivastigmine, clomipramine | CF-EME | 2-ethylhexanol | Wastewater and urine samples | 2.4 ng/mL | >44 | 8.0–500 ng/mL | HPLC-UV | [82] |
| Various drugs and other contaminants | HFLPME | 1-octanol | Water samples | 1.09–98.15 ng/L | 6–4177 | — | UPLC-MS | [83] |
| Ketoprofen, ibuprofen, naproxen, diclofenac | HFLPME | DHE | Urine | 1.6–4.3 μg/L | 43.2–96.8 | 5–500 μg/L | HPLC-DAD | [84] |
| Propranolol, carvedilol, verapamil, amlodipine | HFLPME | Choline chloride + 1-phenylethanol | Urine, plasma, pharmaceutical wastewater | 0.3–0.8 ng/mL | 110–135 | 0.8–500 ng/mL | HPLC-UV | [85] |
| Salicylic acid, ketoprofen, naproxen, ibuprofen, anthranilic acid, nicotinic acid, amoxicillin, hippuric acid | EME | PIM = 29% CTA + 71% Aliquat®336 / 1-octanol | Urine samples | 18–100 μg/L | — | 61–500 μg/L | HPLC-DAD | [86] |
| Pseudoephedrine, lidocaine, propranolol | EME | Polyacrylamide gel as membrane | Breast milk, wastewater | 0.3–6.0 ng/mL | 23.1–29.5 | 1–200 ng/mL | HPLC-UV | [87] |
| Zolpidem | EME | 2-ethylhexanol | Plasma, urine | 3 ng/mL | 75 | 10–1000 ng/mL | HPLC-UV | [88] |
| Indoprofen, ketoprofen, naproxen, ibuprofen | EME | 1-octanol | Urine | 0.20–0.27 μg/mL | — | 0.68–8.4 μg/mL | HPLC-UV | [89] |
| Valproic acid | EME | 1-octanol | Plasma | 0.5 μg/mL | >125 | 0.5–10 μg/mL | HPLC-UV | [90] |
| Amlodipine, verapamil, clomipramine | EME | 2-ethylhexanol | Wastewater, plasma, urine | 3.3–5 μg/L | 98.89–130.3 | 10–2000 μg/L | HPLC-UV | [91] |
| Metaraminol, benzamidine, sotalol, ephedrine, trimethoprim, pethidine hydrochloride, quetiapine, haloperidol, nortriptyline hydrochloride, methadone hydrochloride, loperamide hydrochloride | EME | Phthalate- and nitrile-based organic solvents | Plasma | — | — | — | HPLC-UV | [92] |
| Five fluoroquinolones and four parabens | μEME / LPME | 1-octanol | Urine | 16–75 μg/L | — | 0.25-10 and 0.06–5 μg/mL respectively | HPLC-UV | [93] |
| Diclofenac | HFLPME | 1-octanol | Urine and plasma | 2.8 ng/mL | 170 | 50–2000 ng/mL | HPLC-UV | [94] |
| Exemestane, letrozole, paclitaxel | HFLPME | n-dodecane + TOPO | Urine | 0.3–0.6 μg/L | 152–411 | 0.9–200 μg/L | HPLC-UV | [95] |
| Omeprazole, pantoprazole, lansoprazole | HFLPME | 1-octanol | Plasma | 0.2 μg/mL | 1.5–13 | 0.2–2.0 μg/mL | HPLC-DAD | [96] |
| Phenazopyridine | HFSLPME | 1-octanol | Urine | 0.02 μg/L | — | 0.01–10 μg/L | HPLC-DAD | [97] |
| Different sulfonamides | HFPLME | 1-octanol | Environmental water | 3.1–11.2 ng/L | 14–60 | 0.05–5 μg/L | UHPLC-FLD | [98] |
| Thiabendazole | HFM-MI-MSPE | — | Orange or lemon peel samples | 0.004 mg/kg | — | 0.02–2 mg/L | HPLC-DAD | [99] |
| Leuprolide, triptorelin | EME | 1-octanol + 2-ethyl hexanol + DEHP | Rabbit plasma | 0.15 ng/mL | — | 0.5–1000 ng/mL | HPLC-PAD | [100] |
| Salicylic acid, naproxen, ketoprofen, diclofenac, ibuprofen | EME | 1-octanol | Urine | 0.1–1.5 ng/mL | 85–133 | 0.5–750 ng/mL | HPLC-DAD/FLD | [101] |
| Naproxen, verapamil | EME | 1-octanol, 2-ethylhexanol | Lemon juice, soft drinks | — | — | — | HPLC-UV | [102] |
| Verapamil, riluzole | EME | Mixture of 2-ethyl hexanol and 1-otanol | Urine, wastewater | 1.5–2.5 ng/mL | 123.6–146.6 | 1.5–500 ng/mL | HPLC-UV | [103] |
| Barbital, phenobarbital, pentobarbital | FMLPME | 2-nonanone | Blood, urine, liver | 0.6–10 ng/g | — | 5–2500 ng/g | HPLC-MS | [104] |
| Ciprofloxacin | On chip PEME | 1-octanol | Blood | 1 μg/L | 88 | 2–500 μg/L | HPLC-UV | [105] |
| Nalmefene, diclofenac | On chip-EME | NPOE + DEHP and 1-octanol | Urine | 3–4 μg/L | 17–19 | 9.0–500 μg/L | HPLC-UV | [106] |
| Ezetimibe, simvastatin | CA–HF–SLPME | Cetyl alcohol + 1-octanol | Plasma, urine | 0.363–0.49 μg/L | — | 0.3363–25 μg/L | HPLC-DAD | [107] |
| Fosdanofloxacin, norfloxacin, enrofloxacin, ciprofloxacin | MIP-HFME | Toluene | Environmental water, urine | 0.1–10 μg/L | — | — | HPLC-MS | [108] |
| Raloxifene, ethinylestradiol | HFLPME | 1-octanol + CTAB | Pharmaceutical waste water | 5–10 μg/L | 53–86 | 20–5000 μg/L | HPLC-UV | [109] |
HFDLLME: Hollow fiber dispersive liquid-liquid microextraction, HFLSPME: Hollow fiber liquid solid phase microextraction, PEME: Pulsed electromembrane extraction, CF-EME: Continuous-flow electromembrane extraction, LPME: Liquid phase microextraction, HFM-MI-MSPE: Hollow fiber membrane-molecular imprinted-micro solid phase microextraction, FMLPE: Flat membrane based liquid phase microextraction, CA–HF–SLPME: Cetyl-alcohol-reinforced hollow fiber solid/ liquid phase microextraction, MIP-HFME: Molecular imprinted polymer hollow fiber microextraction, DEHPi: Bis(2-ethylhexyl) phosphite, TFPBA: 4-(trifluoromethyl)phenylboronic acid, RGO: Reduced graphene oxide, TBP: Tributyl phosphate, DHE: Dihexyl ether, PIM: Polymer inclusion membrane, TOPO: Trioctylphosphine oxide HPLC-UV: High performance liquid chromatography with UV detector, HPLC-MS: High performance liquid chromatography with mass spectrometry, HPLC-DAD-FLD: High performance liquid chromatography with diode array detector and fluorescence detector, HPLC-UV-MS: High performance liquid chromatography with UV detector and mass spectrometry, UHPLC-MS: Ultra high performance liquid chromatography with mass spectrometry, HPLC-DAD: High performance liquid chromatography with diode array detector, Fluorometer/RGB/ HPLC-UV: Fluorometer/ Red Green Blue analysis/ High performance liquid chromatography with UV detector.
Limit of detection.
Enrichment factor/Pre-concentration factor.
Linear range.